The Experts below are selected from a list of 7038 Experts worldwide ranked by ideXlab platform
Eli O. Meltzer - One of the best experts on this subject based on the ideXlab platform.
-
impact of azelastine nasal spray on symptoms and quality of life compared with Cetirizine oral tablets in patients with seasonal allergic rhinitis
Annals of Allergy Asthma & Immunology, 2006Co-Authors: William E. Berger, Frank C Hampel, H Sacks, Shailen Shah, Jonathan A. Bernstein, Eli O. MeltzerAbstract:Background In fall 2004, the first Azelastine Cetirizine Trial demonstrated statistically significant improvements in the total nasal symptom score (TNSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores with the use of azelastine nasal spray vs oral Cetirizine in patients with seasonal allergic rhinitis (SAR). Objective To compare the effects of azelastine nasal spray vs Cetirizine on the TNSS and RQLQ scores in patients with SAR. Methods This 2-week, double-blind, multicenter trial randomized 360 patients with moderate-to-severe SAR to azelastine, 2 sprays per nostril twice daily, or Cetirizine, 10-mg tablets once daily. The primary efficacy variable was the 12-hour reflective TNSS (rhinorrhea, sneezing, itchy nose, and nasal congestion). Secondary efficacy variables were individual symptom scores and the RQLQ score. Results Azelastine nasal spray and Cetirizine significantly improved the TNSS and individual symptoms compared with baseline ( P P = .002) and individual domain ( P Conclusions Azelastine nasal spray and Cetirizine effectively treated nasal symptoms in patients with SAR. Improvements in the TNSS and individual symptoms favored azelastine over Cetirizine, with significant differences for nasal congestion and sneezing. Azelastine nasal spray significantly improved the RQLQ overall and domain scores compared with Cetirizine.
-
Cetirizine in patients with seasonal rhinitis and concomitant asthma prospective randomized placebo controlled trial
The Journal of Allergy and Clinical Immunology, 1995Co-Authors: Andrew J Grant, Eli O. Meltzer, Christopher F Nicodemus, Steven R Findlay, Michael M Glovsky, Jay Grossman, Harold B Kaiser, Don Q Mitchell, David S Pearlman, John C SelnerAbstract:Abstract Objective: This study explored the safety and efficacy of Cetirizine for treatment of allergic rhinitis and asthma. Methods: Daily treatment for 6 weeks with Cetirizine 10 mg (93 patients) was compared with placebo treatment (93 patients) in a randomized, double-blind parallel study of patients with allergic rhinitis and asthma. This multicenter study was started just before onset of the fall pollen season. Rhinitis and asthma symptoms were assessed twice daily; spirometry was performed weekly. Results: Placebo-treated patients experienced a worsening of rhinitis symptoms from baseline throughout the study, whereas Cetirizine-treated patients had a significant improvement in rhinitis symptoms at week 1, which was maintained after onset of the pollen season. Asthma symptoms in the Cetirizine group improved from baseline at week 1; symptoms were significantly better than in the placebo group for 5 of 6 weeks of the study. Pulmonary function did not worsen in patients taking Cetirizine or placebo; there were no differences between treatments as determined by spirometry. Albuterol use was less frequent in the Cetirizine-treated patients for every week of the study, but differences did not reach significance. Pseudoephedrine use was similar in both groups. More Cetirizine-treated patients (90%) completed the trial than did placebo-treated patients (74%). Both treatments were well tolerated. Conclusion: Cetirizine 10 mg daily is safe and effective in relieving both upper and lower respiratory tract symptoms in patients with seasonal allergic rhinitis and concomitant asthma. (J ALLERGY CLIN IMMUNOL 1995;95:923-32.)
Nicholas A Soter - One of the best experts on this subject based on the ideXlab platform.
-
Cetirizine and astemizole therapy for chronic idiopathic urticaria a double blind placebo controlled comparative trial
Journal of The American Academy of Dermatology, 1995Co-Authors: Debra L Breneman, Edwin A Bronsky, Gerald L Klein, Harry L Roth, Calvin Treger, James Kalivas, Michael D Tharp, Suzanne Bruce, Nicholas A SoterAbstract:Abstract Background: Cetirizine and astemizole have been shown to be safe and effective in the treatment of patients with chronic idiopathic urticaria. Cetirizine brings about clinical benefit more rapidly. Objective: The purpose of this study was to compare the efficacy of single daily doses of Cetirizine and astemizole in relieving the symptoms of chronic idiopathic urticaria, with particular emphasis on the commencement of action. Methods: Patients with chronic idiopathic urticaria were randomly assigned to relieve either 10 mg of Cetirizine, 10 mg of astemizole, or placebo for 4 weeks in a multicenter doubleblind trial. Patients rated symptom severity each night, and investigators rated symptoms weekly. Results: One hundred eighty-seven patients were enrolled in the trial; 180 were included in the safety analysis and 177 were included in at least one efficacy analysis. Both Cetirizine and astemizole were significantly superior to placebo in relieving symptoms of chronic idiopathic urticaria. Both patients' and investigators' ratings indicated that Cetirizine acted more rapidly. Both active treatments were well tolerated, and the incidence of somnolence did not differ statistically between Cetirizine (14.5%) and astemizole (10.3%). Conclusion: Both Cetirizine and astemizole provide effective relief of the symptoms of chronic idiopathic urticaria with similar side-effect profiles. However, clinical benefit occurs significantly more rapidly with Cetirizine.
John C Selner - One of the best experts on this subject based on the ideXlab platform.
-
Cetirizine in patients with seasonal rhinitis and concomitant asthma prospective randomized placebo controlled trial
The Journal of Allergy and Clinical Immunology, 1995Co-Authors: Andrew J Grant, Eli O. Meltzer, Christopher F Nicodemus, Steven R Findlay, Michael M Glovsky, Jay Grossman, Harold B Kaiser, Don Q Mitchell, David S Pearlman, John C SelnerAbstract:Abstract Objective: This study explored the safety and efficacy of Cetirizine for treatment of allergic rhinitis and asthma. Methods: Daily treatment for 6 weeks with Cetirizine 10 mg (93 patients) was compared with placebo treatment (93 patients) in a randomized, double-blind parallel study of patients with allergic rhinitis and asthma. This multicenter study was started just before onset of the fall pollen season. Rhinitis and asthma symptoms were assessed twice daily; spirometry was performed weekly. Results: Placebo-treated patients experienced a worsening of rhinitis symptoms from baseline throughout the study, whereas Cetirizine-treated patients had a significant improvement in rhinitis symptoms at week 1, which was maintained after onset of the pollen season. Asthma symptoms in the Cetirizine group improved from baseline at week 1; symptoms were significantly better than in the placebo group for 5 of 6 weeks of the study. Pulmonary function did not worsen in patients taking Cetirizine or placebo; there were no differences between treatments as determined by spirometry. Albuterol use was less frequent in the Cetirizine-treated patients for every week of the study, but differences did not reach significance. Pseudoephedrine use was similar in both groups. More Cetirizine-treated patients (90%) completed the trial than did placebo-treated patients (74%). Both treatments were well tolerated. Conclusion: Cetirizine 10 mg daily is safe and effective in relieving both upper and lower respiratory tract symptoms in patients with seasonal allergic rhinitis and concomitant asthma. (J ALLERGY CLIN IMMUNOL 1995;95:923-32.)
Abayomi O Olufade - One of the best experts on this subject based on the ideXlab platform.
-
safety of Cetirizine in infants 6 to 11 months of age a randomized double blind placebo controlled study
The Journal of Allergy and Clinical Immunology, 2003Co-Authors: Estelle F R Simons, Peter Silas, Jay M Portnoy, Joseph Catuogno, Douglass Chapman, Abayomi O OlufadeAbstract:Abstract Background: H 1 -antihistamines are widely used for symptom relief in allergic disorders in infants and children; however, there are few prospective, randomized, double-blind, controlled studies of these medications in young children, and to date, no such studies have been conducted in infants. Objective: This prospective, randomized, parallel-group, double-blind, placebo-controlled study was designed to evaluate the safety of the H 1 -antihistamine Cetirizine, particularly with regard to central nervous system and cardiac effects, in infants age 6 to 11 months, inclusive. Methods: Infants who met the entry criteria for age and had a history of treatment with an H 1 -antihistamine for an allergic or other disorder were randomized to receive 0.25 mg/kg Cetirizine orally or matching placebo twice daily orally for 1 week. Results: The mean daily dose in Cetirizine-treated infants was 4.5 ± 0.7 mg (SD). No differences in all-cause or treatment-related adverse events were observed between the Cetirizine- and placebo-treated groups. A trend was observed toward fewer adverse events and sleep-related disturbances in the Cetirizine group compared with the placebo group. No prolongation in the linear corrected QT interval was observed in Cetirizine-treated infants compared with either baseline values or with values in placebo-treated infants. Conclusions: We have documented the safety of Cetirizine in this short-term investigation, the first randomized, double-blind, placebo-controlled study of any H 1 -antihistamine in infants. Additional prospective, randomized, double-blind, placebo-controlled, long-term studies of Cetirizine and other H 1 -antihistamines are needed in this population. (J Allergy Clin Immunol 2003;111:1244-8.)
Pierre Gervais - One of the best experts on this subject based on the ideXlab platform.
-
onset of action and efficacy of terfenadine astemizole Cetirizine and loratadine for the relief of symptoms of allergic rhinitis
Annals of Allergy Asthma & Immunology, 1997Co-Authors: James H Day, Maureen P Briscoe, Reginald H Clark, Anne K Ellis, Pierre GervaisAbstract:Background Terfenadine, astemizole, Cetirizine, and loratadine are compared in their abilities to produce relief of symptoms of allergic rhinitis. Objective The aim of this study was to compare the onset of action and efficacy of the study medications. Methods One hundred eleven ragweed-sensitive subjects were primed with pollen in the Environmental Exposure Unit. Study entry required adequate symptoms over a 3-hour exposure to 5,000 ± 300 grains/m 3 of ragweed pollen. On the test day, subjects were given a single dose of either terfenadine 60 mg (22), astemizole 10 mg (22), Cetirizine 10 mg (23), loratadine 10 mg (22), or placebo (22) when sufficiently symptomatic after a 60-minute exposure. Allergen levels were maintained and symptoms recorded every 30 minutes. Results Proportions of subjects with clinically important relief were Cetirizine, 69.6%; terfenadine, 54.5%; loratadine, 50.0% astemizole, 40.9%; and placebo, 31.8% but differences weren't significant between treatment groups (P = .119). Survival curves for times to onset of clinically important relief for the four treatment groups were not different ( P = .119). Subjects realizing definitive relief were cetiriazine, 65.2%; terfenadine, 45.5%; loratadine, 31.8%; placebo, 27.3%; and astemizole, 22.7% (P = .023). Survival analysis of onset time for definitive relief found significant differences ( P = .010). The ranking was Cetirizine to terfenadine to loratadine to astemizole (quickest to slowest). Global evaluation based on subject willingness to take the medication again yielded percentages: Cetirizine, 82.6%; terfenadine, 66.7%; astemizole, 63.6%; loratadine, 40.9%; and placebo, 36.4% ( P = .036). Conclusion Cetirizine and terfenadine continuously ranked higher in terms of onset of action and efficacy, while loratadine and astemizole ranked lower. Significance was detected in definitive relief and relative efficacy.